ATO-SR-DM: Automated Telephone Outreach With Speech Recognition to Improve Diabetes Care: A Randomized Controlled Study
Study Details
Study Description
Brief Summary
The purpose of this study is to evaluate the effectiveness of automated telephone outreach with speech recognition to improve diabetes care.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
Randomly allocate a total of 1200 health plan members with diabetes to automated telephone outreach with speech recognition (ATO-SR; N = 600) or usual care (N = 600). The intervention is a series of three calls, using automated calls, originating from the health plan, using interactive speech recognition technology, spaced approximately 4-6 weeks apart, to encourage participants to fulfill the recommended testing (dilated eye examinations, glycated hemoglobin, LDL-cholesterol, microalbumin) that had not been performed received in the preceding year.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: ATO-SR Automated Telephone Outreach with Speech Recognition |
Behavioral: Automated Telephone Outreach with Speech Recognition
Automated Telephone Outreach with Speech Recognition
|
| No Intervention: Usual Care Usual Care |
Other: Usual Care
Usual Care
|
Outcome Measures
Primary Outcome Measures
- Completion of dilated eye examination [12-months following intervention]
Secondary Outcome Measures
- Completion of glycated hemoglobin testing (HbA1c) [one-year following intervention]
- Completion of LDL-cholesterol testing [one year following intervention]
- Completion of microalbumin testing [one-year following intervention]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age 18 years or older
-
Diabetes, defined as either 1) filled a prescription for insulin or an oral hypoglycemic agent; or, 2) had two outpatient or one inpatient or two outpatients encounter claims with an ICD9-CM or CPT code indicating diabetes.
-
Gap in a key diabetes management metric as evidenced by no claim for a dilated eye examination in the prior 15 months and no claim for one or more of the following tests: glycated hemoglobin, LDL-cholesterol, or microalbumin. (Individuals with evidence of having received ACE-inhibitors or angiotensin receptor blockers were considered to have had a microalbumin test.)
Exclusion Criteria:
-
No primary care clinician in the data base
-
Those who had previously asked the health plan to exclude them from research or quality improvement
-
Women whose claim records contained diagnoses suggesting gestational diabetes
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Harvard Pilgrim Health Care | Boston | Massachusetts | United States | 02215 |
Sponsors and Collaborators
- Harvard Pilgrim Health Care
- American Diabetes Association
Investigators
- Principal Investigator: Steven R Simon, MD, Harvard Pilgrim Health Care
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 1-05-JF-40